As of 2 p.m. New York time, Vaxart (VXRT), a biotech developing a coronavirus vaccine in a pill, was up 48.26% to $9.04. It closed up 37.46% The stock had traded 151 million shares as of 2 p.m., about 11 times the average volume over the last 60 days. I think what we’re seeing is another one of those speculative moves built on a possible news event–Vaxart has announced a webinar for May 3 that is expected to include the release of new Phase 1 data on the efficacy of its Cover-19 vaccine in a pill–plus a plausible story–a vaccine in a pill would be exactly what India needs to stop its current pandemic surge and a vaccine in a pill would be helpful in convincing some of the vaccine hesitant to get vaccinated (no needle)–plus a big short position. According to Seeking Alpha short positions account for about 20.4% of total outstanding shares.
I thought there was a possibility that Vaxart (VXRT) would recover from yesterday’s 60% drop on data from the initial Phase 1 trials of its coronavirus-vaccine-in-a-pill candidate. Especially because the initial reaction over-emphasized, in my opinion, the negatives in that data. But I suspected that yesterday’s downward trend would continue for at least another day and therefore chose to sell Vaxart shares out of my Volatility Portfolio.
As of 3:00 p.m. New York time today, February 3, shares of Vaxart (VXRT) were down 58.50% to $9.69 on news that although its coronavirus vaccine candidate triggered several immune responses, it did not produce the neutralizing antibodies that prevent sa virus from replicating. I will sell shares out of my Volatility Portfolio tomorrow
Ok, I don’t want to see “the next GameStop under every rock.” But Vaxart (VXRT) deserves a look or two. (The stock is a member of my Volatility Portfolio where it’s up 5.27 as of the close on February 1 since I added it to the portfolio on July 22, 2020. I also own shares in my personal portfolio.) Here’s what I see with the shares of this company that is in clinical trials of a vaccine for the coronavirus. Vaxart’s vaccine is a pill and it’s the only vaccine pill under development. Shares of Vaxart are up (as of the February 1 close) 54.93% in the last week and 172.68% in the last month. They’ve added 216.46% in the last 3 months and are up 172.68% for 2021 to date as of the close on February 1. The shares moved up another 29.97% today to $15.57 a share.
I looked at my Jubak Picks Portfolio with more than a tinge of seller’s remorse this morning. I sold shares of First Majestic Silver (AG) out of that portfolio on Friday, January 29, after the stock rose 21.38% on Thursday. That gave me a gain of 45.52% since I began this position on July 6, 2019.I argued in justification for this sell that the attempt by individual investors on Reddit’s WallStreetBets forum to force a short squeeze in silver, as they had in GameStop (GME), were likely to fail because there was such a big stockpile of physical silver ready to enter the market. So I took my profit. Only to have the stock climb an other 21.3% today, February 1, as of 2:30 p.m. New York time as individual investors did indeed drive up the price of silver futures. The Shares Silver Trust (SLV) was up 6.40% as of 2:30 New York time today as the intraday price of silver limbed to the highest level since 2013. And then I thought about that seller’s remorse.